Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07137364) titled 'Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism' on Aug. 3.

Study Type: Observational [Patient Registry]

Primary Sponsor: Third Military Medical University

Condition: Primary Aldosteronism Hypertension

Intervention: Drug: spironolactone

Recruitment Status: Recruiting

Date of First Enrollment: May 1, 2022

Target Sample Size: 350

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07137364

Published by HT Digital Content Services with permission from Health Daily Digest....